ANXA1 antibody - N-terminal region (ARP36569_P050)
- Known as:
- ANXA1 (anti-) - N-terminal region (ARP36569_P050)
- Catalog number:
- arp36569_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ANXA1 antibody - N-terminal region (ARP36569_P050)
Related genes to: ANXA1 antibody - N-terminal region (ARP36569_P050)
- Gene:
- ANXA1 NIH gene
- Name:
- annexin A1
- Previous symbol:
- ANX1, LPC1
- Synonyms:
- -
- Chromosome:
- 9q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2014-11-19
Related products to: ANXA1 antibody - N-terminal region (ARP36569_P050)
Related articles to: ANXA1 antibody - N-terminal region (ARP36569_P050)
- Head and neck cancer (HNC) is characterized by substantial immune heterogeneity and limited availability of clinically actionable molecular targets. Here, we developed an integrative single-cell eQTL-driven multi-omics framework to identify immune cell-specific causal genes and prioritize drug-repurposing candidates for HNC. - Source: PubMed
Publication date: 2026/08/06
Xue ZhangweiShen GuohangLin GongbiaoXue HanzhenWang RuoyanZhou YueChen YangWang KaiyongDai Yupei - Ovarian cancer has the highest mortality among gynecologic malignancies, and acquired resistance to paclitaxel severely limits its clinical efficacy. - Source: PubMed
Li ZhouMingrui JiangYueyang ZhouHang QiQing LiuXiaoyu YanHuimei YuMeihui Xia - Vemurafenib (VEM) is a BRAF inhibitor that improves the prognosis of melanoma, but acquired resistance represents a key limitation to its clinical efficacy. This study investigated the potential of A11, an Annexin A1 (ANXA1)-derived peptide, to enhance VEM efficacy in both VEM-sensitive and VEM-resistant melanoma cells. We evaluated the effects of A11 in melanoma through in vitro assays (including MTT, clonogenic survival, apoptosis, and cell cycle analysis) and in vivo xenograft models in nude mice. Furthermore, we mechanistically interrogated A11-mediated suppression of EphA2 expression and the downstream pS897-EphA2/AKT/ERK signalling pathway in resistant and parental cell lines via Western blotting and immunohistochemistry (IHC). Critically, our study demonstrates that A11 inhibits melanoma cell proliferation and reverses VEM resistance through EphA2 downregulation, consequently ablating this oncogenic pathway. This research highlights the promising application value of A11 in improving the efficacy of VEM treatment in melanoma, particularly in VEM-resistant melanoma. - Source: PubMed
Feng JuanHuang Xiao-PuZhang MingHuang WeiLu Shan-ShanXiao Zhi-QiangXie Zhi-HaiYi Hong - Annexin A1 (ANXA1) is a multifunctional regulatory protein involved in neuroinflammation and cellular homeostasis, but its role in amyotrophic lateral sclerosis (ALS) remains unclear. In this study, we investigated the relationship between ANXA1 and Hippo pathway signaling in ALS. Bioinformatic analysis of transcriptomic data from iPSC-derived motor neurons showed that ANXA1 expression was reduced in ALS and associated with apoptosis and Hippo pathway-related changes. Decreased ANXA1 expression was confirmed in hSOD1^G93A transgenic mice and NSC34 motor neuron-like cells. Phosphorylation levels of MST1/2, LATS1/2, and YAP1 were elevated, indicates activation of the Hippo pathway. Functional experiments showed that ANXA1 overexpression reduced Hippo pathway activation, enhanced cell viability, and decreased apoptosis, as increased Bcl-2 expression and reduced Bax and cleaved caspase-9 levels. In contrast, ANXA1 knockdown further activated Hippo pathway and aggravated apoptotic changes. These findings identify ANXA1 as an upstream regulator associated with Hippo pathway activation in ALS and suggest that the ANXA1/Hippo axis may represent a potential therapeutic target. - Source: PubMed
Publication date: 2026/08/17
Zhang YingDong XinyuShai YaoAlam MasoodHan DidiHu YujingHe ZhonghuiZhou ZhenqiJiang Hongquan - Bovine leukemia virus (BLV) is an oncogenic retrovirus that naturally infects cattle. Once infected, the virus persists indefinitely throughout life at a transcriptionally silent stage. Soon after infection, humoral and cytotoxic activities efficiently abolish the viral replicative cycle, allowing only mitotic expansion of provirus-carrying cells. These anti-viral activities persist throughout the animal's life indicating that the immune system is permanently stimulated by BLV antigens. Although protein production is abolished during the chronic stage, viral transcription is not completely shut down. Extracellular vesicles (EVs) are nano-sized lipid bilayer vesicles released from most cells and play multiple roles in cell-to-cell communication, including immune modulation, angiogenesis, and transformation of cells by transferring genetic material and functional proteins. Colostrum is rich in EVs that carry bioactive proteins and RNAs reflecting maternal physiology and immune status. In this study, we aimed to characterize how BLV infection influences the protein cargo of colostrum-derived EVs. - Source: PubMed
Publication date: 2026/07/29
Pérez Cecilia ValeriaCarignano Hugo AdriánMarchetti Yamila CelesteGonzález Diego DanielRuiz VanesaTrono Karina GabrielaMongini Claudia